IGF1 and ovarian carcinoma: In experimental models of ovarian carcinoma, PAPP-A has been demonstrated to enhance IGF activity and accelerate tumor growth [12–15], whereas PAPP-A neutralization has been shown to reduce tumor growth and delay the formation of ascites [16].